Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free UCBJF Stock Alerts
OTCMKTS:UCBJF

UCB (UCBJF) Stock Price, News & Analysis

UCB logo
$246.11 +10.45 (+4.44%)
As of 03:09 PM Eastern
Compare

About UCB Stock (OTCMKTS:UCBJF)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$241.48
▼
$250.59
50-Day Range
$231.75
▼
$295.59
52-Week Range
$228.94
▼
$345.39
Volume
288 shs
Average Volume
679 shs
Market Capitalization
$46.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders. UCB also develops additional therapies across neurological and immunological indications, including treatments for rare diseases.

Founded in 1928, UCB has grown from a chemical and pharmaceutical business into an international biopharmaceutical company headquartered in Brussels, Belgium. It serves patients and healthcare professionals through commercial operations and partnerships across Europe, North America, Asia and other international markets.

AI Generated. May Contain Errors.

Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UCBJF Stock News Headlines

Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection
August 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/stacy-ku-initiates-buy-on-ucb-citing-attractive-valuation-and-early-bimzelx-driven-growth-inflection-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
May 3, 2026  |  reuters.comhttps://www.reuters.com/legal/transactional/belgian-pharma-group-ucb-buy-candid-therapeutics-up-22-billion-2026-05-03/
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
September 28 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B
April 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4576267-belgian-pharma-ucb-buy-us-based-neurona
Belgium's UCB in autoimmune drug deal with Antengene
March 3, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/belgiums-ucb-autoimmune-drug-deal-with-antengene-2026-03-04/
Day by Day maintains UCB (UCBJF) buy recommendation
December 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/day-by-day-maintains-ucb-ucbjf-buy-recommendation/ar-AA1Su13Z
UCB price target raised to EUR 300 from EUR 230 at JPMorgan
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/ucb-price-target-raised-to-eur-300-from-eur-230-at-jpmorgan/ar-AA1RXfAq
UCB removed from European Conviction List at Goldman Sachs
November 4, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/ucb-removed-from-european-conviction-list-at-goldman-sachs/ar-AA1PIlfl
See More Headlines

UCBJF Stock Analysis - Frequently Asked Questions

UCB's stock was trading at $293.58 on January 1st, 2026. Since then, UCBJF shares have decreased by 16.2% and is now trading at $246.1125.

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
9/28/2026
Fiscal Year End
12/31/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:UCBJF
CIK
1290640
Web
www.ucb.com
Phone
(322) 559-9999
Fax
32-2559-9900
Employees
9,083
Year Founded
1928

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.33
Current Ratio
1.19
Quick Ratio
0.78

Sales & Book Value

Annual Sales
$5.27 billion
Price / Sales
8.83
Cash Flow
$10.57 per share
Price / Cash Flow
23.28
Book Value
$50.52 per share
Price / Book
4.87

Miscellaneous

Outstanding Shares
189,020,000
Free Float
N/A
Market Cap
$46.52 billion
Optionable
Not Optionable
Beta
0.47

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (OTCMKTS:UCBJF) was last updated on 9/28/2026 by MarketBeat.com Staff.
From Our Partners
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel